
Beyond Air, Inc.
Nasdaq · Surgical & Medical Instruments & Apparatus
Company Overview
A concise company profile alongside the latest public filing activity.
Beyond Air develops nitric oxide generation and delivery systems for treating respiratory conditions, including a device that produces high-concentration nitric oxide gas for hospital use in treating pulmonary hypertension in newborns. The company is also researching nitric oxide-based therapies for viral and fungal lung infections and solid tumor treatment.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Lin Yi-Chien10% Owner | Buy | $43K | 15,393at $2.80 | Oct 1, 2026 |
| Lin Yi-Chien10% Owner | Buy | $8K | 3,000at $2.69 | Sep 29, 2026 |
| Lin Yi-Chien10% Owner | Buy | $5K | 2,000at $2.71 | Sep 30, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable XAIR activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.